Share this story:

Ventripoint Diagnostics Ltd. Announces Filing of Second Amended and Restated MD&A

Ventripoint Diagnostics Ltd.


Toronto, Canada – TheNewswire - October 13, 2021 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT), (OTC:VPTDF), announces that as a result of a review by staff of the Ontario Securities Commission (“OSC”) it is issuing the following press release to clarify its previous disclosure. The Company has filed a second amended and restated management’s discussion and analysis for the three and six month period ended June 30, 2021 (the “Second Revised MD&A”).


The Second Revised MD&A was refiled to, among other things, provide enhanced disclosure of the Company’s projects, plans, expenditures made and the timing and costs anticipated to advance the Company’s projects to the next stage.  The Business Objectives and Milestones discussion in the Second Revised MD&A has been revised to include details with respect to the Company’s sales efforts and strategy, General Electric  Healthcare collaboration, VMS+4.0 timing, product design and development programs, and commercialization.


The revisions reflected in the Revised MD&A have been made at the request of OSC staff in connection with their review of the Company’s preliminary short form prospectus dated October 1, 2021.



Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.  For more information, please visit



Dr. George Adams



This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at

Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.